Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

SIMPLE SUMMARY: Immunotherapy has made a breakthrough in the treatment of patients with recurrent and/or metastatic head and neck squamous cell carcinoma in the second line setting with anti-PD-1/PD-L1 immune checkpoint inhibitors. Furthermore, the KEYNOTE-048 study has established a new standard of...

Descripción completa

Detalles Bibliográficos
Autores principales: Borcoman, Edith, Marret, Gregoire, Le Tourneau, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197177/
https://www.ncbi.nlm.nih.gov/pubmed/34073885
http://dx.doi.org/10.3390/cancers13112573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197177/
https://www.ncbi.nlm.nih.gov/pubmed/34073885
http://dx.doi.org/10.3390/cancers13112573

Ejemplares similares